Advancing Predictive Oncology: Artificial Intelligence for Early Cancer Detection, Risk Stratification, and Personalized Treatment

Abstract

The growing complexity of cancer biology, characterized by extensive molecular heterogeneity, temporal evolution, therapeutic resistance, and variable clinical outcomes, has created significant challenges for conventional oncology practice. Traditional cancer management strategies have primarily relied on imaging findings, histopathological assessment, and individual molecular markers, often providing an incomplete representation of the multidimensional processes that drive tumor development and progression. In response, predictive oncology has emerged as an innovative paradigm that utilizes artificial intelligence (AI), digital biomarkers, multi-omics integration, radiogenomics, and continuously generated clinical data to support early cancer detection, individualized risk stratification, and precision-guided therapeutic decision-making. By leveraging machine learning, deep learning, transformer-based models, and multimodal foundation architectures, predictive oncology enables the analysis of complex datasets derived from radiological imaging, digital pathology, genomics, transcriptomics, proteomics, liquid biopsies, wearable health technologies, and electronic health records. These advanced computational approaches facilitate the identification of subtle disease-associated patterns, prediction of tumor progression, assessment of treatment responsiveness, and optimization of personalized cancer care pathways. Recent developments in AI-enabled oncology have substantially improved cancer screening programs, prognostic modeling, recurrence prediction, survival forecasting, digital pathology interpretation, immunotherapy response evaluation, and adaptive treatment planning. Deep learning algorithms, including convolutional neural networks and transformer-based frameworks, have demonstrated high-performance capabilities in the automated analysis of medical images and histopathological specimens, often approaching expert-level accuracy. Furthermore, multimodal AI systems integrating molecular, radiological, and clinical information have accelerated the discovery of predictive biomarkers that support precision medicine across diverse malignancies. Nevertheless, important challenges remain, including issues related to model transparency, algorithmic fairness, data harmonization, privacy protection, regulatory validation, and integration into routine clinical workflows. This review examines the emergence of predictive oncology and explores the expanding role of artificial intelligence in early cancer detection, digital biomarker identification, clinical risk prediction, and precision therapy. Additionally, the article discusses emerging technologies including multimodal learning frameworks, explainable AI systems, federated oncology infrastructures, and future translational opportunities that may shape the next generation of intelligent precision oncology.